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Background
The prevalence of psychiatric disorders is increased in
children and adults with intellectual disability. Brain
damage or dysfunction interacts with social and family
factors to increase susceptibility to mental illness. Current
concepts in drug therapy often attempt treatment of large
patient populations as groups, irrespective of the potential
for individual, genetically-based differences in drug
response.
Materials and methods
This article aims to give an overview of the exciting discov-
eries made so far in the field of psychiatry, as well as to
mention some of the more recent findings.
Results
Clinical outcome to psychiatric drug therapy varies widely
among patients, and is complicated by variability in indi-
vidual response to psychotropic drugs. The activity of psy-
chiatric drugs can also be influenced by genetic alterations
affecting the drug target molecule. These include the
dopaminergic and serotonergic receptors, neurotransmit-
ter transporters and other receptors and enzymes involved
in psychiatric disorders.
Association studies investigating the relation between
genetic polymorphisms in metabolic enzymes and neuro-
transmitter receptors on psychiatric treatment outcome
provide a step towards the individualization of psychiatric
treatment through enabling the selection of the most ben-
eficial drug according to the individual's genetic back-
ground.
Discussion
New developments in molecular biology, human
genomic information, statistical methods, and bioinfor-
matics are ongoing and could pave the way for the next
generation of pharmacogenetic studies in psychiatry.
Knowledge from these studies will ultimately lead to the
individualization of psychiatric drug treatment, while
providing new insights into the etiology of these disorders
and their future treatment.
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